Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

globenewswire.com
GILD Gilead Sciences' Kite Pharma is a leading company in the CAR T-cell therapy market for Non-Hodgkin's Lymphoma, with approved products like YESCARTA and TECARTUS contributing to market growth. The company is well-positioned to benefit from the expanding market. NVS Novartis is a key player in the CAR T-cell therapy market for NHL with its product KYMRIAH and is developing next-generation therapies like Rapcabtagene autoleucel. The company is poised to benefit from market expansion and innovation. BMY Bristol Myers Squibb is an active participant in the CAR T-cell therapy market for NHL with its product BREYANZI. The company is expected to benefit from the overall market growth driven by increasing adoption and innovation. CRSP CRISPR Therapeutics is developing investigational CAR T-cell therapies like CTX110 for NHL. The company's involvement in next-generation therapies positions it to capitalize on the expanding market and treatment innovation. BIO Mustang Bio is developing the investigational CAR T-cell therapy MB-106 for NHL. Its participation in the emerging therapies pipeline suggests potential growth as the CAR T-cell market expands and innovates. ADBT Adicet Bio is listed as an active company in the CAR T-cell therapy market for NHL. While its specific contributions are not detailed, its presence indicates potential involvement in the growing market. BIIB While Biogen is not explicitly mentioned as a developer of CAR T-cell therapies for NHL in this article, its broader presence in the biotech and healthcare sector means it could be indirectly impacted by market trends. However, no direct sentiment can be derived. JNJ Johnson & Johnson is listed as an active company in the CAR T-cell therapy market for NHL. Its involvement suggests it is a player in this growing therapeutic area, poised to benefit from market expansion and innovation. REGN Regeneron Pharmaceuticals is not explicitly mentioned in relation to CAR T-cell therapy for NHL in this article. Therefore, no specific sentiment or hot market classification can be assigned based on this content. AMGN Amgen is not explicitly mentioned in the context of CAR T-cell therapy for NHL in this article. Therefore, no specific sentiment or hot market classification can be assigned based on this content. CELC Cellectis' TALEN technology is mentioned as being used by Allogene Therapeutics for an investigational CAR T-cell candidate. This indicates a positive role in the development of next-generation therapies within a growing market. ALLO Allogene Therapeutics is developing the investigational allogeneic CAR T-cell candidate Cemacabtagene ansegedleucel (Allo-501A) using Cellectis technology. This positions them to benefit from the expansion of CAR T-cell therapies. MBIO Mustang Bio is developing the investigational CAR T-cell therapy MB-106 for NHL. Its participation in the emerging therapies pipeline suggests potential growth as the CAR T-cell market expands and innovates. AUTL Autolus Therapeutics is listed as an active company in the CAR T-cell therapy market for NHL. While its specific contributions are not detailed, its presence indicates potential involvement in the growing market.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

CAR T-Cell Therapy in Non-Hodgkin's Lymphoma Market Poised for Continued Growth Through 2036

The chimeric antigen receptor (CAR) T-cell therapy market in non-Hodgkin's lymphoma (NHL) reached approximately USD 3.20 billion across the seven major markets-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-in 2025. The market is forecast to expand at a compound annual growth rate of approximately 7% from 2026 to 2036, supported by broader clinical adoption, new indications, earlier-line use, and continued innovation in autologous and allogeneic CAR T-cell platforms.

The report, Chimeric Antigen Receptor (CAR) T-Cell Therapy in Non-Hodgkin's Lymphoma (NHL)-Market Insights, Epidemiology and Market Forecast-2036, provides a comprehensive assessment of historical and forecast epidemiology, treatment practices, market size, therapy uptake, pricing, competitive dynamics, and unmet medical needs across the 7MM.

CAR T-Cell Therapy Market Highlights

CAR T-cell therapy has reshaped treatment for patients with relapsed or refractory B-cell malignancies by enabling deep and durable responses after prior therapies have failed. Approved products, including YESCARTA, KYMRIAH, BREYANZI, and TECARTUS, have established CAR T-cell treatment across diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, marginal zone lymphoma, and other eligible B-cell malignancies.

Market growth is being driven by rising NHL incidence, increasing physician experience, improvements in patient identification, and expanding use in second-line and selected earlier treatment settings. CAR T-cell therapy also offers an alternative to salvage chemotherapy and autologous stem cell transplantation for eligible patients with high-risk, primary refractory, or early-relapsing disease.

Competitive Landscape and Emerging CAR T-Cell Therapies

The CAR T-cell therapy pipeline for NHL includes next-generation autologous products and allogeneic candidates intended to improve manufacturing speed, product consistency, accessibility, safety, and response durability. Investigational therapies include CTX110, zamtocabtagene autoleucel, cemacabtagene ansegedleucel, rapcabtagene autoleucel, and MB-106.

Cemacabtagene ansegedleucel, also known as ALLO-501A, is an investigational anti-CD19 allogeneic CAR T-cell candidate developed by Allogene Therapeutics using Cellectis TALEN technology. Rapcabtagene autoleucel, developed by Novartis through its T-Charge platform, has demonstrated promising early clinical activity in diffuse large B-cell lymphoma.

Leading companies active in the CAR T-cell therapy market include Gilead Sciences' Kite Pharma, Novartis, Bristol Myers Squibb, Miltenyi Biomedicine, Wugen, Autolus Therapeutics, 2seventy bio, Imugene, Mustang Bio, CRISPR Therapeutics, Tessa Therapeutics, Johnson & Johnson, Adicet Bio, Juno Therapeutics, and Takeda.

Recent CAR T-Cell Therapy Developments

Unmet Needs and Market Opportunities

Despite significant clinical progress, the NHL CAR T-cell therapy market continues to face barriers related to cytokine release syndrome, neurotoxicity, treatment eligibility, manufacturing timelines, prior authorization, specialist-center capacity, and total treatment cost. Development of readily available allogeneic therapies could reduce delays associated with individualized manufacturing while extending treatment access to a broader patient population.

The United States is expected to retain its market leadership through 2036 because of earlier regulatory approvals, established treatment infrastructure, higher adoption of advanced therapies, and faster integration of new indications. Germany currently holds the largest market share within the EU4 and the United Kingdom, followed by Italy, while Spain represents the smallest assessed European market. Japan and the European markets are nevertheless positioned for steady growth as access improves and novel products enter clinical practice.

Report Coverage

The report includes epidemiology-based market forecasting from 2022 to 2036, patient population analysis, therapy-specific revenue projections, drug uptake and peak patient-share assessments, pricing trends, pipeline profiles, clinical development analysis, treatment algorithms, and regional market opportunities. It also incorporates SWOT and conjoint analyses alongside perspectives from key opinion leaders across major cancer research and treatment institutions.

Overall, expanding indications, movement into earlier treatment lines, stronger clinical evidence, and advances in allogeneic manufacturing are expected to intensify competition and sustain growth in the CAR T-cell therapy in non-Hodgkin's lymphoma market through 2036. Diffuse large B-cell lymphoma is projected to remain the leading revenue-generating indication in the United States, while mantle cell lymphoma and follicular lymphoma represent important areas for future clinical and commercial expansion.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

4.1. Upcoming Key Catalysts

4.2. Key Transactions And Collaborations

4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. CAR T- cell in NHL Market Overview at a Glance

6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)

6.2. Market Share (%) Distribution of CAR T-cells in NHL by Therapies in the 7MM, in 2025

6.3. Market Share (%) Distribution of CAR T-cells in NHL by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

7.1. Introduction

7.2. Understanding Lymphoma

7.2.1. Types of Lymphoma

7.2.2. Types of NHL

7.3. Signs and Symptoms

7.4. Staging

7.5. Diagnosis of NHL

8. Treatment of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

9. Treatment Guidelines

9.1. NCCN Guidelines for Diffuse Large B-Cell Lymphoma

9.2. NCCN Guidelines for Follicular Lymphoma

10. Epidemiology and Patient Population of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

10.1. Key Findings

10.2. Assumptions and Rationale

10.3. Epidemiology Scenario in the 7MM

10.4. The United States

10.4.1. Total NHL incident cases in selected subtypes in the United States

10.4.2. Total eligible cases of NHL for CAR-T in the United States

10.5. EU4 and the UK

10.5.1. Total NHL incident cases in selected subtypes in the EU4 and the UK

10.5.2. Total eligible cases of NHL for CAR-T in the EU4 and the UK

10.6. Japan

10.6.1. Total NHL incident cases in selected subtypes in Japan

10.6.2. Total eligible cases of NHL for CAR-T in Japan

11. Patient Journey of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

12. Marketed Therapies

12.1. Marketed Competitive Landscape of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

12.2. YESCARTA (axicabtagene ciloleucel): Gilead Sciences (Kite Pharma)

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activities

12.2.4. Summary of Pivotal Trials

12.2.5. Clinical Development

12.2.5.1. Clinical Trial Information

12.2.6. Analyst's Views

12.3. KYMRIAH (tisagenlecleucel): Novartis

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activities

12.3.4. Summary of Pivotal Trials

12.3.5. Clinical Development

12.3.5.1. Clinical Trial Information

12.3.6. Analyst's Views

12.4. BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Other Developmental Activities

12.4.4. Summary of Pivotal Trials

12.4.5. Clinical Development

12.4.5.1. Clinical Trial Information

12.4.6. Analyst's Views

12.5. TECARTUS (brexucabtagene autoleucel): Gilead Sciences (Kite Pharma)

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activities

12.5.4. Summary of Pivotal Trials

12.5.5. Analyst's Views

13. Emerging Drugs

13.1. Emerging Competitive Landscape of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

13.2. Rapcabtagene autoleucel: Novartis

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.3.1. Clinical Trials Information

13.2.4. Analyst's Views

13.3. Zamtocabtagene autoleucel: Miltenyi Biomedicine

13.3.1. Drug Description

13.3.2. Other Developmental Activity

13.3.3. Clinical Development

13.3.3.1. Clinical Trials Information

13.3.4. Analyst's Views

13.4. MB-106: Mustang Bio

13.4.1. Drug Description

13.4.2. Clinical Development

13.4.2.1. Clinical Trial Information

13.4.3. Safety and Efficacy

13.4.4. Analyst's Views

13.5. CTX110: CRISPR Therapeutics

13.5.1. Drug Description

13.5.2. Clinical Development

13.5.2.1. Clinical Trial Information

13.5.3. Safety and Efficacy

13.5.4. Analyst's Views

13.6. bbT369: 2seventy bio

13.6.1. Drug Description

13.6.2. Clinical Development

13.6.2.1. Clinical Trial Information

13.6.3. Safety and Efficacy

13.6.4. Analyst's Views

13.7. Azercabtagene zapreleucel: Imugene

13.7.1. Drug Description

13.7.2. Clinical Development

13.7.2.1. Clinical Trial Information

13.7.3. Safety and Efficacy

13.7.4. Analyst's Views

14. Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL): 7MM Analysis

14.1. Key Findings

14.2. Market Outlook of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

14.3. Key Market Forecast Assumptions

14.3.1. Cost Assumptions

14.4. Conjoint Analysis of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

14.4. Total Market Size of CAR T- Cell in NHL in the 7MM

14.4. Total Market Size of CAR T- Cell in NHL by Therapies in the 7MM

14.4. The United States

14.7.1. Total Market Size of CAR T- Cell in NHL in the United States

14.7.2. Total Market Size of CAR T- Cell in NHL by Therapies in the United States

14.8. EU4 and the UK

14.8.1. Total Market Size of CAR T- Cell in NHL in EU4 and the UK

14.8.2. Total Market Size of CAR T- Cell in NHL by Therapies in EU4 and the UK

14.9. Japan

14.9.1. Total Market Size of CAR T- Cell in NHL in Japan

14.9.2. Total Market Size of CAR T- Cell in NHL by Therapies in Japan

15. Unmet Needs of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

16. SWOT Analysis of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

17. KOL Views of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

18. Market Access and Reimbursement of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

18.1. The United States

18.2. EU4 and the UK

18.2.1. Germany

18.2.2. France

18.2.3. Italy

18.2.4. Spain

18.2.5. United Kingdom

18.3. Japan

18.3. Summary and comparison of Market Access and Pricing Policy Developments in 2025

18.3. Market Access and Reimbursement of CAR T- CELL IN NHL Therapies

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. Analyst's Capabilities

21. Disclaimer

22. About the Publisher

List of Tables

Table 1: Summary of CAR-T in NHL Market and Epidemiology (2022-2036)

Table 2: Lugano Modification of the Ann Arbor Staging System

Table 3: Treatment for Relapse - Under 12 months

Table 4: Second-line Therapy Options if Hematopoietic Cell Transplant (HCT) Planned

Table 5: Total Incident Cases of Selected Indications for CAR-T in NHL in the 7MM (2022-2036)

Table 6: Total Indication wise Eligible Cases of CAR-T in NHL in the 7MM (2022-2036)

Table 7: Comparison of Marketed Products

Table 8: YESCARTA, Clinical Trial Description, 2022

Table 9: KYMRIAH, clinical trial description, 2022

Table 10: BREYANZI, Clinical Trial Description, 2022

Table 11: TECARTUS, Clinical Trial Description, 2022

Table 12: Comparison of Emerging Drugs

Table 13: Cemacabtagene ansegedleucel, Clinical Trial Description, 2022

Table 14: Rapcabtagene autoleucel, Clinical Trial Description, 2022

Table 15: Zamtocabtagene autoleucel, Clinical Trial Description, 2022

Table 16: MB-106, Clinical Trial Description, 2022

Table 17: CTX110, Clinical Trial Description, 2022

Table 18: bbT369, Clinical Trial Description, 2022

Table 19: Azercabtagene zapreleucel, Clinical Trial Description, 2022

Table 20: Key Market Forecast Assumption of CAR-T in NHL in the US

Table 21: Key Market Forecast Assumption of CAR-T in NHL in EU4 and the UK

Table 22: Key Market Forecast Assumption of CAR-T in NHL in Japan

Table 23: Market Size by Indications in the US (2022-2036)

Table 24: Market Size of CAR-T in NHL by Indications in the US (2022-2036)

Table 25: Market Size of CAR-T in NHL by Therapies in the US, USD million (2022-2036)

Table 26: Market Size of CAR-T in NHL by Indications in EU4 and the UK, USD million (2022-2036)

Table 27: Market Size of CAR-T in NHL by Therapies in EU4 and the UK, USD million (2022-2036)

Table 28: Market Size of CAR-T in NHL by Indications in Japan (2022-2036)

Table 29: Market Size of CAR-T in NHL by Therapies in Japan, USD million (2022-2036)

Table 30: A Summary Overview of List Prices, Reimbursement Schemes, and key Outcomes Associated With the Reimbursement of CAR-T cell Therapies in the EU4 (Germany, France, Italy, and Spain) and the UK

List of Figures

Figure 1: Types of Lymphomas

Figure 2: Most Common Subtypes of Non-Hodgkin Lymphoma (NHL)

Figure 3: Manufacturing and Delivery of CAR-T Cells

Figure 4: Generations of CAR-T cells

Figure 5: Total Incident Cases of Selected Indications for CAR-T in NHL in the 7MM (2022-2036)

Figure 6: Total Indication wise Eligible Cases of CAR-T in NHL in the 7MM (2022-2036)

Figure 7: Total Market Size of CAR-T in NHL in the 7MM (2022-2036)

Figure 8: Market Size of CAR-T in NHL by Indications in the US (2022-2036)

Figure 9: Market Size of CAR-T in NHL by Therapies In the US (2022-2036)

Figure 10: Market Size of CAR-T in NHL by Indications in EU4 and the UK (2022-2036)

Figure 11: Market Size of CAR-T in NHL by Therapies EU4 and the UK (2022-2036)

Figure 12: Market Size of CAR-T in NHL by Indications in Japan (2022-2036)

Figure 13: Market Size of CAR-T in NHL by Therapies in Japan (2022-2036)

Figure 14: Health Technology Assessment

Figure 15: Reimbursement Process in Germany

Figure 16: Reimbursement Process in France

Figure 17: Reimbursement Process in Italy

Figure 18: Reimbursement Process in Spain

Figure 19: Reimbursement Process in the United Kingdom

Figure 20: Reimbursement Process in Japan

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/mhjx8a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.